Introduction
Human immunodeficiency virus type 1 (HIV-1) infection causes the acquired immune deficiency syndrome (AIDS), which still remains a major public health concern. Combination antiretroviral therapy (cART), typically consisting of three or more antiretroviral (ARV) drugs, effectively blocks ongoing replication of HIV-1 to the undetectable level in peripheral blood. Due to the increased access to HIV-1 treatment globally, cART has significantly reduced the risk of HIV transmission and improved the life expectancy of HIV-infected patients. However, cART is unable to completely eliminate HIV-1, which exists in latent reservoirs that are the source of residual viremia, even in the presence of ARV drugs (Ruelas and Greene, 2013; Siliciano and Greene, 2011) . Because of these reservoirs viruses would rebound if treatment were interrupted, patients are required to adhere to HIV-1 medicine for life (Garcia et al., 2012; Siliciano and Greene, 2011) . Given that the development of a safe and effective HIV-1 vaccine still remains unsuccessful (Garcia et al., 2012; Pollara et al., 2017) , a cure strategy to eliminate residual HIV-1 is attractive. Such a strategy would bypass the downside of cART and restore complete health.
Resting memory CD4 þ T cells are considered to be a major HIV-1 latent reservoir. In most activated CD4 þ T cells, HIV-1 infection causes a virus-induced cytopathic effect and cell apoptosis.
However, some are survive and revert back to their resting state, forming the HIV-1 latent reservoirs (Ruelas and Greene, 2013; Siliciano and Greene, 2011) . These cells harbor replication competent, but transcriptionally silent HIV-1 proviruses, which still retain the capability to produce infectious HIV-1 virions (Archin et al., 2014; Ruelas and Greene, 2013; Siliciano and Greene, 2011) . Extensive efforts have been taken to explore the ''shock and kill'' cure strategy to purge latently infected HIV-1 proviruses in reservoir cells. This strategy relies on the use of latency reversing agents (LRAs) to reactivate latent HIV-1 proviruses in cART-treated AIDS patients, which would theoretically eliminate latent reservoirs by virus-induced cell death and/or HIV-1-specific cytolytic T lymphocytes (CTLs) (Xing and Siliciano, 2013) . Although numerous studies have shown that certain LRAs or LRA combinations effectively reverse HIV-1 latency in CD4 þ T cells isolated from HIVpositive, cART-treated AIDS patients ex vivo (Darcis et al., 2015; Laird et al., 2015) , use of only LRAs does not lead to the killing of HIV-1 latently infected CD4 þ T cells. Additionally, HIV-1 antigenspecific stimulation of CTLs prior to HIV-1 reactivation is required (Shan et al., 2012) . A recent clinical trial study also showed that administration of histone deacetylase inhibitors (HDACis) in HIVpositive, cART-treated AIDS patients fails to reduce the size of HIV-1 latent reservoirs although viral latency is successfully reversed (Archin et al., 2012) . Combined these results suggest that the ''shock and kill'' cure strategy still faces major obstacles that are difficult to overcome. Since the ''shock and kill'' strategy still requires significant efforts to solve the above issues, other alternative strategies have been explored to reach an HIV-1 cure (Darcis et al., 2017; Mousseau et al., 2015b) . One is to "block" the occasional reactivation of HIV-1 proviruses so that integrated proviruses are "locked" in a deep and permanent latency. The problem is that cART is unable to eliminate the low-level replication of HIV-1. Since no drug component in cART inhibits HIV-1 transcription, there is still sporadically reactivated HIV-1 expression ("blip") that continues the replenishment of HIV-1 latent reservoir and maintains its persistence. For the "block and lock" strategy, latency-promoting agents (LPAs) will be complemented with cART regimen to suppress resurrected viral transcription and reduce the residual viremia (Darcis et al., 2017; Mousseau et al., 2015b) . Such combination treatment will facilitate the decay of HIV-1 latent reservoir and significantly reduce its size (Darcis et al., 2017; Mousseau et al., 2015b) . Once the viral load is under the control, LPAs alone would continue to reinforce the deep and irreversible latency of HIV-1 and the permanent silencing of HIV-1 proviruses even without cART, which would eventually lead to the elimination of HIV-1 latent reservoir and a functional cure of HIV-1. It would also allow the disruption of cART and the reduction of its side effects (Mousseau et al., 2015b) . Recently several potential LPAs have been identified (Darcis et al., 2017) . For example, one promising LPA is didehydro-Cortistatin A (dCA), which selectively inhibits HIV-1 Tat-mediated viral transcription (Mousseau et al., 2012) . The dCA and cART combination is able to block the reactivation of latently infected HIV-1 proviruses in CD4 þ T cells from HIV-positive, cART-treated AIDS patients (Mousseau et al., 2015a) . However its long-term effect on reinforced and irreversible latency of HIV-1 proviruses still needs further investigation. Tat-mutated HIV-1 viruses may arise and cause drug resistance since dCA targets Tat, a viral protein. Expansion of new potential LPAs will benefit the further exploration of this "block and lock" cure strategy and facilitate the development of an effective therapy to eliminate HIV-1 residual viremia. In this study, we screened an FDA-approved compound library, composed of 978 unique small-molecule compounds, and identified Levosimendan as a novel and promising anti-HIV-1 inhibitor that warrants further investigation.
Material and methods

Cells
The following cell lines were kindly provided by the NIH AIDS reagent program: Jurkat Clone E6-1 (Cat. #177), J-LAT A2 (Cat. #9854), 6.3 (Cat. #9846) and 10.6 (Cat. #9849), and JLTRG (Cat. #11586). The HIV-1 latently infected T cell lines CA5 and EF7 were kindly provided by Olaf Kutsch (University of Alabama) (Duverger et al., 2014) . All T cell lines were maintained in RPMI 1640 medium supplemented with 10% FBS. Peripheral Blood Mononuclear Cells (PBMCs) from HIV-1 and HIV-2 negative healthy donors was purchased from Stemcell technologies (Cat. #70025) and were cultured in complete media (RPMI 1640, 10% FBS, 1 Â glutamine, 1 Â MEM non-essential amino acid solution, 20 mM HEPES) containing 30 IU/ml IL-2.
Viruses and plasmids
HIV-1 IIIB wild type strain was kindly provided by the NIH AIDS reagent program. VSV-G pseudotyped HIV-1 NL4-3 luciferase virus (HIV-1 Luc) or retroviruses expressing HIV-1 Tat (pQCXIP-Tat) were created as described previously Power et al., 2015) .
Compounds and reagents
FDA approved compound screening library (978 compounds, 10 mM solution in DMSO, L1300) was purchased from Selleckchem. For the validation of the selected compounds, we separately ordered levosimendan (Cat. #S2446, SelleckChem; Cat. #L5545, Sigma), spironolactone (Cat. #S4054, SelleckChem; Cat. #S3378, Sigma), 9-aminoacridine (Cat. #92817, Sigma), and mycophenolic acid (Cat. #S2487, SelleckChem; Cat. #M3536, Sigma). Images of compound's chemical structure shown in figures were obtained from Sigma-Aldrich. Recombinant human TNFa (Cat. #BD 554618) was purchased from BD Bioscience. 3 0 -Azido-3 0 -deoxythymidine (AZT, Cat. #A2169) was purchased from Sigma. Raltegravir (RAL, Cat. #S2005) were purchased from SelleckChem. 3-Methyladenine (3-MA, Cat. S2767) was purchased from SelleckChem. Anti-human CD3 antibody (Cat. #16-0037-85) and anti-human CD28 antibody (Cat. #16-0289-85) were purchased from eBioscience.
Compound screen
An FDA approved compound screening library (978 compounds, 10 mM solution in DMSO) was used for the compound screening.
Each compound was diluted to 500 mM solution in DMSO for the compound screen, or diluted to 50, 5, 0.5, 0.05, or 0.005 mM solution in DMSO for titration experiments of selected compounds. Compounds were kept at À80 C before use. 384 well plates (Cat. #3712, Corning) were treated with 50 mg/ml fibronectin (Sigma) in D-PBS for 2 h at 37 C to allow the floating cells to attach the surface of the wells (Yamazoe et al., 2009 ). The compounds (0.7 mL) or DMSO as a control were then added in 20 mL of RPMI-10% FBS to fibronectintreated wells. 50 mL of media containing J-LAT A2 cells (1 Â 10 4 cells per well) and TNFa were then added. The final concentration of TNFa or DMSO was 10 ng/ml or 1%, respectively. Plates were then spun down, and incubated for 24 h at 37 C. After 24 h, cell nuclei were stained with D-PBS containing 2 mg/ml Hoechst ® 33342 (Life technologies). The cells were imaged using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek) and the percentages of GFP positive cells and cell numbers in each well were determined by counting GFP and Hoechst positive cells using Gen5 Imageþ software (BioTek).
Flow cytometry
HIV-1 latently infected cell lines (4 Â 10 5 cells per ml) were cotreated with 10 ng/ml TNFa and indicated compounds. After 24 h, GFP-positive cells were analyzed by flow cytometry (BD Accuri™ C6, BD). JLTRG cells (4 Â 10 5 cells per ml) in 24 well plate were pretreated with the indicated compounds for 6 h. The cells were transduced with retroviruses expressing HIV-1 Tat (pQCXIP-Tat) or pQCXIP-empty for 48 h before flow cytometry. The results were analyzed using FlowJo software (v10.0.7).
Cell viability assay
Cell viability upon drug treatment was determined using CellTiter-Glo ® Luminescent Cell Viability Assay (Promega) or LIVE/ DEAD™ Fixable Green Dead Cell Stain Kit (Invitrogen).
Measurement of HIV-1 transcripts
Cells (4 Â 10 5 cells per ml) were co-treated with 10 ng/ml TNFa and indicated compounds. After 24 h, cells were collected and subjected to RNA extraction (RNeasy mini kit, QIAGEN), cDNA synthesis (iScript™ cDNA Synthesis Kit, Bio-Rad), and qPCR analysis using the iTaq™ Universal SYBR ® Green Supermix (Bio-Rad) as described previously Zhu et al., 2012) . We used initiation primers (Ini) targeting bp 10e59 of HIV-1 transcript, proximal primers targeting bp 29e180 of HIV-1 transcript, intermediate primers targeting bp 836e1015 of HIV-1 transcript, distal primers targeting bp 2341e2433 of HIV-1 transcript, and GAPDH primers for normalization. Primer sequences were described previously (Zhu et al., 2012) .
Measurement of HIV-1 late RT product
Jurkat cells (5 Â 10 5 cells per ml) were pretreated with the indicated compounds for 6 h, and then infected with HIV-1 IIIB virus (4.5 ng of HIV-1 p24 per 5 Â 10 5 cells) for 18 h. The cells were collected and subjected to DNA extraction (DNeasy Blood & Tissue Kit, QIAGEN) and qPCR analysis to measure late RT and mitochondrial DNA products using TaqMan ® Universal PCR Master Mix (Life technologies) as described previously (Butler et al., 2001; Zhu et al., 2014) .
Co-immunoprecipitation (Co-IP) and western blot
Co-immunoprecipitation and western blot analysis was performed as described previously Power et al., 2015) . Briefly, HeLa cells stably expressing Tat-Flag were treated with levosimendan (10 mM) for 24 h. Total cell lysates were subjected to western blot analysis using Flag antibody (Cat. #14793, Cell signaling), PARP antibody (Cat. #9542, Cell signaling), or GAPDH antibody (Cat. #sc-47724, Santa Cruz). For Co-IP experiments, total cell lysates were immunoprecipitated using Protein A/ G Magnetic Beads (Thermo scientific) with Flag antibody (Cat. #8146, Cell signaling). Immunoprecipitated proteins were subjected to western blot analysis using cyclin T1 antibody (Cat. #sc-10750, Santa Cruz).
Acute HIV-1 infection in primary CD4
þ T cells CD4 þ T cells were isolated from healthy donor PBMCs by
The cells were stimulated with anti-CD3/CD28 antibodies (2 mg/ ml of each) for 3 days. The activated CD4 þ T cells were then infected with HIV-1 IIIB strain (10 ng of p24 per 10 6 cells) for 6 h.
The inoculum was removed, and the cells were washed once in D-PBS. The cells were cultured in complete media containing IL2 (30 UI/ml). Media and drugs were replaced every 3 days. On days 3, 6, 9 or 12 post infection, the supernatant was harvested and subjected to HIV-1 p24 ELISA using HIV-1 p24 antigen capture assay kit (ABL inc ).
2.11. HIV-1 latency model using primary CD4 þ T cells
To determine the effect of the drugs on reactivation of latent HIV-1 ex vivo, we utilized Planelles' model with slight modifications Planelles, 2009, 2011) . Briefly, CD4
þ T cells isolated from healthy donor PBMCs were stimulated with anti-CD3/CD28
antibodies (2 mg/ml of each) in the presence of TGF-b1 (10 ng/ ml), anti-human IL-12 (2 mg/ml), and anti-human IL-4 (1 mg/ml) for 3 days. The activated cells were cultured in the presence of IL-2 (30 UI/ml) for 4 days. The activated CD4 þ T cells were then spinoculated with HIV-1 Luc (5 ng of p24 per 10 6 cells) at 1741 Â g for 2 h at 37 C.
Cells were then incubated in complete media containing IL-2 (30 UI/ml) for 7 days to establish HIV-1 latency. Finally, cells were stimulated with anti-CD3/CD28 antibodies (1 mg/ml of each) in the presence of LSM (10 mM) or SPR (10 mM) for 3 days. The level of HIV-1 reactivation was then determined by measuring luciferase activity using ONE-Glo™ Luciferase Assay System (Promega).
HIV-1 reactivation in CD4
þ T cells isolated from cART-treated,
HIV-infected aviremic patients
PBMCs were isolated from fresh whole blood of cART-treated, HIV-infected aviremic patients as described previously (Huang et al., 2017) . The CD4 þ T cells isolated from PBMCs (2 Â 10 6 cells per well) were then stimulated with anti-CD3/CD28 antibodies
(1 mg/ml of each) in the presence of LSM (10 mM) or SPR (10 mM). On day 3, media and drugs were replaced. On day 6, the supernatant was harvested and subjected to RNA extraction followed by ultra-sensitive qPCR assay to quantify reactivated HIV viruses as described previously (Huang et al., 2017; Mousseau et al., 2015a) . A serial dilution of HIV-1 IIIB RNAs with known copy numbers were used to create standard curve for calculation of copy number of HIV RNAs in supernatant.
HIV-infected subjects
cART-treated, HIV-infected aviremic patients were recruited from the AIDS clinic at the Strong Memorial Hospital of University of Rochester Medical Center (Rochester, New York). All patients signed informed consents to enroll in this study. All subjects were treated with cART for >3 years, had an undetectable plasma HIV RNA level (<50 copies/ml) for at least 6 months, and a normal CD4 þ T lymphocyte count (>300 cells/mm 3 ) at the time of leukapheresis process. This study was approved by the University of Rochester Research Subjects Review Board with an assigned number (#RSRB00053667).
Data analysis and statistics
Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's multiple-comparison test (GraphPad Prism 5.0 software). A p value of <0.05 was considered statistically significant. Dose response curve was created by nonlinear regression model, and the 50% inhibitory concentration (IC 50 ) and the cytotoxic concentration (CC 50 ) was calculated using GraphPad Prism 5.0 software.
Results
A screen of FDA-approved compounds identifies new anti-HIV-1 inhibitor candidates
We screened an FDA-approved compound library to identify novel anti-HIV-1 agents, using the HIV-1 latency cell line, J-LAT A2, which contains an HIV-1 minigenome "LTR-tat-IRES-GFP", to determine the drug effect on TNFa-induced HIV-1 reactivation through the measurement of GFP-positive cell population Jordan et al., 2003) . J-LAT A2 cells were plated on fibronectin-treated 384 well plates and grown as a monolayer (Yamazoe et al., 2009) , so that quantification of the GFP-positive cell population could be determined using fluorescence microscopy. Cells were treated with TNFa (10 ng/ml) and individual compounds (5 mM) for 24 h. Nuclei were then stained using Hoechst ® 33342 for quantification purposes (Fig. 1A) . TNFa induced the expression of GFP in the majority of J-LAT A2 cells (87.2%), whereas un-treated cells mostly remained GFP-negative (Fig. 1B) . We then determined the relative percentage of GFPpositive cells (% GFP-positive) and the relative total cell numbers (% cell numbers) by normalizing the results of compound-treated cells to DMSO-treated cells in each plate (Table S1 ). Screening results were plotted as % GFP-positive vs % cell numbers (Fig. 1C) . From this experiment we identified two FDA-approved compounds, levosimendan and 9-aminoacridine, which reduced the % GFP-positive by 50%, while the compound-treated cells remains % cell numbers over 50%. Levosimendan is a cardiostimulatory drug used for treatment of heart failure through increasing the sensitivity of troponin-C to calcium and enhancing the contractility of myocardium (Kasikcioglu and Cam, 2006; Nieminen et al., 2013) . So far there is no reported antiviral effect of levosimendan. However, 9-aminoacridine is known to inhibit HIV-1 transcription through the Tat protein (Guendel et al., 2009) . At the time that these initial screenings were completed, there was a timely report showing that spironolactone suppresses HIV-1 transcription. However there was no experimental evidence measuring the effect of spironolactone on HIV-1 latency (Lacombe et al., 2016) . Although spironolactone only inhibits HIV-1 reactivation by 40%, we included spironolactone in further studies to evaluate its effect as an anti-HIV-1 inhibitor. Next, we performed titration experiments for all compounds that reduce the % GFP-positive by 50%, regardless of their cytotoxicity at lower concentrations, in a series of 10-fold dilution ranging from 0.05 to 500 nM, which was used to calculate the compound's IC 50 and CC 50 values (Fig. S1 , Table S2 ). Although cytotoxicity is reduced at lower concentrations for these compounds, most of their anti-reactivation effect is also abolished, making them less ideal as antiviral compound candidates. However, among these compounds we selected mycophenolic acid and its ester derivative, mycophenolate mofetil, as they potently inhibited HIV-1 reactivation in J-LAT A2 cells at the concentration of 5 mM with moderate cytotoxicity, for further validation (Table S1 , Fig. S1 ). Mycophenolic acid is known to block HIV-1 reverse transcription through inhibition of the de novo synthesis of guanosine nucleotides (Chapuis et al., 2000; Ichimura and Levy, 1995) .
Levosimendan inhibits HIV-1 reactivation in latency cell lines
Next we performed more profound experiments, titrating our five selected compounds (levosimendan, spironolactone, 9-aminoacridine, mycophenolic acid, and mycophenolate mofetil) in a series of 2-fold dilutions ranging from 0.625 to 20 mM, onto J-LAT A2 cells that were treated with TNFa to induce HIV-1 reactivation. GFP-positive cells were quantified using flow cytometry for this round of titration experiments. Treatment with levosimendan and spironolactone lead to a significant reduction of HIV-1 reactivation in a dose-dependent manner, while the cytotoxicity was subtle in all doses tested ( Fig. 2A) . Treatment with 9-aminoacridine showed a significant anti-reactivation effect as well, however it was also more cytotoxic at higher doses. Compound's IC 50 values were determined accordingly (levosimendan: 3.8 mM; spironolactone, 3.7 mM; 9-aminoacridine, 2.4 mM) (Table S2) . Mycophenolic acid and mycophenolate mofetil demonstrated a very similar inhibitory effect in J-LAT A2 cells, with the same IC 50 value of 0.6 mM (Fig. S2A , Table S2 ). To confirm the identity of compounds within our library, we repeated tests using identical compounds from different sources; results in J-LAT A2 cells were comparable (Fig. S2B) . We further tested our anti-HIV-1 inhibitor candidates (levosimendan, spironolactone, 9-aminoacridine, mycophenolic acid) in multiple HIV-1 latency cell lines harboring HIV-1 proviral genomes. We used J-LAT 6.3 and J-LAT 10.6 cell lines harboring replication-incompetent, env-deleted HIV-1 NL4-3 GFP provirus (Jordan et al., 2003) , and CA5 and EF7 cell lines which are latently infected with replicationcompetent HIV-1 NL4-3 GFP virus (Duverger et al., 2014) . Treatment with levosimendan and spironolactone blocked the TNFainduced HIV-1 reactivation in all tested HIV-1 latency cell lines in a dose-dependent manner (Fig. 2BeE) . However, treatment of 9-aminoacridine failed to block reactivation in these HIV-1 latency cell lines and even slightly enhanced HIV-1 reactivation in J-LAT 6.3 cells (Fig. 2BeE) . Although treatment of mycophenolic acid mildly blocked HIV-1 reactivation in J-LAT 6.3 cells, it showed no inhibitory effect on other cell lines (Fig. S3) . In parallel, we measured compound cytotoxicity in these HIV-1 latency cell lines, and all compounds showed minimal cytotoxicity at the tested concentrations in the presence of TNFa or HIV-1 Tat (Figs. S4AeE) . Likewise, there was no or minor cytotoxicity either in Jurkat cells that were only treated with the compound alone (Fig. S4F) . Collectively, these results suggest that levosimendan, similarly to spironolactone, is able to potently block reactivation of latent HIV-1 proviruses without severe cytotoxicity.
Levosimendan suppresses HIV-1 Tat-LTR mediated transcription
We further measured the effect of levosimendan and spironolactone on HIV-1 transcription as they were shown to potently block TNFa-induced HIV-1 reactivation. First we determined the effect of levosimendan and spironolactone on HIV-1 transcription by qPCR assay, using primers that measure HIV-1 transcripts at different sites. Both compounds potently inhibited transcriptional initiation and elongation to a similar extent in TNFa-treated J-LAT 10.6 and CA5 cells (Fig. 3AeB) . We next determined the effect of levosimendan and spironolactone on HIV-1 5' LTR promoter activity in the presence of HIV-1 Tat protein. We transduced the JLTRG cells, which harbor an integrated LTR-GFP construct, with a retroviral vector (pQCXIP) expressing FLAG-Tat to induce GFP expression. Both compounds reduced the percentage of GFP-positive cells, although the inhibitory effect of levosimendan seems greater than that of spironolactone and 9-aminoacridine, both of which were known to inhibit Tat-LTR mediated transcription (Guendel et al., 2009; Lacombe et al., 2016) . However, both levosimendan and spironolactone showed no inhibitory effect on HIV-1 reverse transcription (Fig. 3D) , suggesting that these compounds may specifically target the HIV-1 transcription step.
Levosimendan blocks HIV-1 replication and reactivation in primary CD4
þ cells
As all of the above experiments were performed using Jurkat-derived cell lines, we chose to verify the compound's antiretroviral effect in more physiologically relevant, primary CD4 þ T cells. We tested the cytotoxicity of levosimendan and spironolactone in primary CD4 þ T cells. Levosimendan showed no cytotoxicity, while there was moderate cytotoxicity of spironolactone on day 3 posttreatment (Fig. S4G) . We then verified the effect of levosimendan and spironolactone (10 mM) on acute replication of HIV-1 IIIB in activated primary CD4 þ T cells isolated from 3 healthy donors.
Levosimendan completely inhibited HIV-1 replication in all tested CD4 þ T cells (Fig. 4A) . Although spironolactone also showed the inhibitory effect, it was much weaker than that of levosimendan (Fig. 4A ). Next we tested the effect of levosimendan and spironolactone on HIV-1 reactivation in HIV-1-Luc latently infected primary CD4 þ T cells, a cell model of HIV-1 latency that was established by Vicente Planelles' group Planelles, 2009, 2011) . Treatment with levosimendan and spironolactone efficiently blocked anti-CD3/CD28-induced HIV-1 reactivation in all tested CD4 þ T cells isolated from the three healthy donors comparably (Fig. 4B) . We further evaluated the effect of levosimendan and spironolactone on HIV-1 reactivation in primary CD4 þ T cells that were isolated from 3 cART-treated, HIV-infected aviremic patients. Both levosimendan and spironolactone significantly inhibited anti-CD3/CD28-induced HIV-1 reactivation (Fig. 4C) . Although levosimendan consistently showed no obvious cytotoxicity, spironolactone still caused moderate cytotoxicity (Fig. 4D) .
Levosimendan inhibits HIV-1 reactivation through phosphoinositide 3-kinase (PI3K) pathway
As the next step, we would have liked to understand the molecular mechanism that underlines the inhibitory effect of levosimendan on HIV-1 transcription. Since HIV-1 Tat protein plays a key role in viral transcriptional elongation through the interaction with positive transcription elongation factor b (P-TEFb) complex, composed of cyclin T1 and cyclin-dependent kinase 9 (Kamori and Ueno, 2017), we first determined the effect of levosimendan on Tat protein level and Tat-P-TEFb protein interaction in Tat-expressing HeLa cells. Neither the Tat protein level nor the Tat-P-TEFb protein interaction was affected by the treatment of levosimedan (Fig. 5AeB) . We also ruled out the anti-HIV effect of levosimendan is through the induction of cell apoptosis. Treatment of levosimendan in Tat-expressing HeLa cells is unable to induce the cleavage of PARP, a hallmark of cell apoptosis (Fig. S5) . A previous study showed that overexpression of constitutively active PI3K reduced HIV-1 transcription, whereas PI3K inhibitors enhance it, suggesting that PI3K pathway negatively regulates HIV-1 transcription (Cook et al., 2002) . Interestingly, it has also been reported that levosimendan inhibits oxidative injuries, caused by hydrogen peroxide, in rat cardiac cells, and PI3K inhibitor, 3-MA, compromised such effect (Uberti et al., 2011) . These previous findings led us to hypothesize that levosimendan may activate PI3K pathway to suppress HIV-1 transcription. Indeed, our results showed that treatment of 3-MA is able to restore the reactivated HIV-1 expression that was suppressed by levosimendan in a dosedependent manner in J-LAT 10.6 cells (Fig. 5C ).
Discussion
In this study, we screened an FDA-approved compound library and successfully identified levosimendan as a novel and promising anti-HIV-1 inhibitor. We found that this drug suppresses HIV-1 reactivation in all tested HIV-1 latency cell lines, primary CD4
þ T cell models of HIV-1 latency, as well as the primary CD4 þ T cells that were isolated from cART-treated, HIV-infected aviremic patients (Figs. 2 and 4B-C). Levosimendan is a calcium-sensitizing positive inotropic drug used for treatment of acutely decompensated heart failure (Kasikcioglu and Cam, 2006; Nieminen et al., 2013; Pathak et al., 2013) . This drug has multiple mechanisms of action, including 1) enhanced cardiac contractility by increasing the sensitivity of troponin-C to calcium without affecting the intracellular calcium level, 2) vasodilation, through opening the ATPsensitive potassium (KATP) channel, 3) phosphodiesterase (PDE) III inhibition activity, and 4) cardioprotection possibly through the anti-inflammatory and anti-apoptotic effects (Kivikko et al., 2003; Nieminen et al., 2013; Pathak et al., 2013) . Whether these functions of levosimedan associate with inhibition of HIV-1 reactivation remains unclear at this stage. Interestingly, our screening results also showed that pimobendan, a known calcium sensitizer and PDE III inhibitor, does not efficiently suppress TNFa-induced HIV-1 reactivation in J-LAT A2 cells (Table S1 ) (Pollesello et al., 2016) . We further titrated pimobendan with a series of 2-fold dilutions ranging from 0.625 to 20 mM in J-LAT A2 cells. Results
showed that there was only subtle inhibition of TNFa-induced HIV-1 reactivation even at a high concentration of 20 mM (Fig. S2C ). This suggests that levosimendan's suppressive effect on HIV-1 reactivation could be independent of its calcium sensitizing and PDE III inhibitory activities. Our studies suggest that levosimendan specifically suppresses HIV-1 transcription since it has no effect on HIV-1 reverse transcription (Fig. 3D) . We further confirmed that levosimendan blocks HIV-1 Tat-LTR mediated transcription (Fig. 3C) . However, our results showed that the inhibitory effect of levosimendan on HIV-1 transcription and reactivation is not through the direct reduction of either Tat protein level or the Tat-P-TEFb protein interaction (Fig. 5AeB) . It is possible that the inhibitory effect of levosimendan relates to its interference with the TNFa-mediated NF-kB pathway, which is required for HIV-1 transcription. A previous study has shown that levosimendan suppresses NF-kB-mediated transcription, although the inhibitory effect seems to be moderate (approximately 30% reduction) even when levosimendan was used at a high concentration (10 mM) (Sareila et al., 2008) . However, a PI3K inhibitor, 3-MA, is sufficient to overcome the inhibitory effect of levosimendan and restore the HIV-1 reactivation in a dosedependent manner (Fig. 5C ), suggesting that levosimendan may activate the PI3K pathway to suppress HIV-1 transcription and reactivation. Further investigations are needed to further unravel the mechanism(s) relevant to the antiretroviral effect of levosimendan.
A pharmacological study of levosimendan in patients with heart failure showed that maximum plasma concentration (C max ) is reached at approximately 0.43 mM after intravenous administration of levosimendan (Kivikko et al., 2003) . The IC 50 of levosimendan determined in J-LAT A2 cells is approximately 9 times higher than the C max in vivo, although the effective concentration in cell culture in vitro cannot be simply compared with the in vivo situation (Blaauboer, 2008) . Further in vivo studies are required to determine the optimal concentration of levosimedan that is able to effectively block HIV-1 reactivation in the clinical setting. It has been reported that levosimendan, within the range from 1 nM to 10 mM, increases calcium sensitization in a dose-dependent manner in primary guinea pig myocytes (Szilagyi et al., 2004 (Szilagyi et al., , 2005 . In contrast, a higher concentration of levosimendan is required to exert its cytoprotective effect against the apoptosis in primary rat cardiac fibroblasts (30e100 mM) or to activate the KATP channel in rat ventricular cells (EC 50 ¼ 4.7 mM) (Okada and Yamawaki, 2015; Yokoshiki et al., 1997) . Therefore, a higher concentration of levosimendan might be needed to result in other actions, which could be apart from its calcium sensitizing effect.
In addition to levosimendan, our screen also identified spironolactone as an anti-HIV-1 agent. Spironolactone is currently used as a potassium-sparing diuretic, in clinics, to treat hypertension, hyperaldosteronism, and heart failure (Lainscak et al., 2015) . Very recently, this drug has been reported to inhibit acute HIV-1 infection through the inhibition of Tat-mediated HIV-1 transcription (Lacombe et al., 2016) . However, the effect of spironolactone on HIV-1 latency has never been tested. For the first time, our results show that spironolactone potently blocks HIV-1 reactivation in HIV-1 latency cell lines and primary CD4 þ T cells harboring latently infected HIV-1 proviruses (Figs. 2and 4B-C) . Spironolactone, together with levosimendan, could be immediately moved to clinical studies for further investigation since they are FDAapproved compounds.
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